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 Supplementary Fig. S1. Design of the nested case-cohort study in EPIC-Potsdam with randomly drawn 
sub-cohort and incident cases of type 2 diabetes   
Supplementary Table S1. Baseline characteristics in EPIC-Potsdam and KORA F4 
 EPIC-Potsdam KORA F4 
N (%women) 2283 (61.8) 2818 (47.6) 
Age at baseline in years 49 (15) 55 (22) 
BMI in kg/m² 25.5 (5.18) . 
Waist circumference in cm 85.0 (18.8) . 
Hexose in µmol/L 4556 (886) 4962 (781) 
Glycine in µmol/L 241 (85.0) 295 (93.0) 
Isoleucine + Leucine in µmol/L 200 (69.0) 206 (59.0) 
Phenylalanine in µmol/L 54.9 (13.3) 61.0 (13.5) 
Tryptophan in µmol/L 80.0 (15.1) 82.6 (12.6) 
Tyrosine in µmol/L 78.6 (27.4) 83.2 (23.2) 
Valine in µmol/L 286 (83.0) 270 (83.0) 
C3 in µmol/L 0.36 (0.18) 0.37 (0.15) 
PC ae C32:1 in µmol/L 2.81 (0.79) 2.81 (0.87) 
PC ae C32:2 in µmol/L 0.71 (0.22) 0.74 (0.24) 
PC ae C34:2 in µmol/L 13.0 (4.60) 12.4 (4.50) 
PC ae C34:3 in µmol/L 8.21 (3.11) 8.17 (3.12) 
PC ae C36:2 in µmol/L 16.8 (5.60) 14.8 (5.30) 
PC ae C36:3 in µmol/L 9.36 (2.93) 8.47 (2.80) 
PC ae C40:5 in µmol/L 3.91 (1.01) 3.52 (0.88) 
PC ae C40:6 in µmol/L 5.36 (1.81) 4.90 (1.70) 
PC ae C42:3 in µmol/L 0.84 (0.25) 0.85 (0.27) 
PC ae C42:4 in µmol/L 0.92 (0.29) 0.99 (0.33) 
PC ae C42:5 in µmol/L 2.30 (0.67) 2.30 (0.64) 
PC ae C44:4 in µmol/L 0.37 (0.13) 0.42 (0.14) 
PC ae C44:5 in µmol/L 1.72 (0.60) 2.06 (0.71) 
PC ae C44:6 in µmol/L 1.14 (0.40) 1.34 (0.48) 
PC aa C32:1 in µmol/L 14.7 (10.0) 19.0 (11.8) 
PC aa C36:1 in µmol/L 55.4 (17.7) 51.8 (16.5) 
PC aa C36:3 in µmol/L 149 (43.0) 147 (42.0) 
PC aa C38:3 in µmol/L 53.5 (18.2) 52.2 (17.7) 
PC aa C40:4 in µmol/L 3.83 (1.34) 3.94 (1.40) 
PC aa C40:5 in µmol/L 10.9 (4.32) 11.0 (3.80) 
PC aa C42:0 in µmol/L 0.58 (0.22) 0.57 (0.22) 
PC aa C42:1 in µmol/L 0.29 (0.11) 0.29 (0.10) 
SM C16:1 in µmol/L 17.3 (4.70) 15.6 (4.60) 
SM (OH) C22:2 in µmol/L 12.0 (4.31) 11.2 (3.83) 
LysoPC a C17:0 in µmol/L 1.94 (0.77) 1.68 (0.69) 
LysoPC a C18:2 in µmol/L 33.2 (17.0) 25.9 (12.1) 
Age, BMI, waist circumference and 34 diabetes-associated metabolites are depicted as  
medians (interquartile range) 
 
Supplementary Table S2. Replicated genetic variants associated with diabetes-associated metabolite traits in EPIC-Potsdam 
SNP Reported 
Locus 







MAF Metabolite trait N β (95% CI) a p-value b Adj. R² in 
% 
rs541503 c PHGDH 1 intron variant 4.82 C 37.5 Glycine/Serine 2204 
0.1677 
(0.1071 -0.2283 ) 
6.31E-08 2.87 
rs715 d CPS1 2 3 prime UTR variant 3.20 C 30.1 Glycine 2196 
0.5870 
(0.5277 -0.6464 ) 
1.81E-77 16.1 
              Glycine/Serine 2197 
0.4895   
(0.4286 -0.5504 ) 
3.77E-53 11.7 
              Serine/Phenylalanine 2197 
0.1763  
 (0.1137 -0.2388 ) 
3.65E-08 6.76 
rs12641551 c ACSL1 4 intron variant 3.93 G 31.9 
PC ae C44:5/ 
PC ae C42:5  
2202 
0.2533 
(0.1915 -0.3150 ) 
1.36E-15 3.47 
              
PC ae C44:6/ 
PC aa C42:1  
2203 
0.1347  
 (0.0728 -0.1966 ) 
2.04E-05 2.87 
rs272893 c SLC22A4, OCTN1 5 Ile306Thr 12.57 A 38.4 
PC ae C44:5/ 
PC ae C42:5  
2202 
0.1406  
 (0.0812 -0.2000 ) 
3.70E-06 1.59 
rs9393903 c ELOVL2 6 intron variant 2.19 A 24.5 
PC aa C40:4/ 
PC aa C42:6 
2240 
0.1582  
 (0.0915 -0.2249 ) 
3.52E-06 3.11 
              
PC aa C40:5/ 
PC aa C42:5  
2240 
0.2276  
 (0.1624 -0.2928 ) 
9.74E-12 7.50 
              
PC aa C40:5/ 
PC aa C40:6  
2241 
0.1499   
(0.0836 -0.2161 ) 
9.59E-06 4.43 
rs603424 c SCD 10 intron variant 6.86 A 18.7 
PC ae C42:5/ 





              
SM (OH) C22:2/ 





              
SM C16:1/ 





              PC aa C36:3/ 2192 0.1745  4.32E-06 2.89 
PC aa C34:3   (0.1002 -0.2488 ) 
              
PC aa C32:1/ 




              






















              
PC ae C34:1/ 
PC ae C32:1  
2200 
0.1593  
 (0.0987 -0.2199 ) 
2.75E-07 2.91 
              
PC  ae C34:2/ 
PC ae C38:5  
2204 
0.4321  
 (0.3770 -0.4872 ) 
8.09E-51 19.7 
              
PC ae C34:2/ 
PC ae C36:4  
2203 
0.4302  
 (0.3749 -0.4855 ) 
4.60E-50 19.1 
              
PC ae C34:2/ 





              
PC aa C36:3/ 
PC aa C36:5  
2201 
0.3573  
 (0.2991 -0.4155 ) 
2.39E-32 10.3 
              
PC ae C36:3/ 
PC ae C38:5  
2204 
0.5707   
(0.5178 -0.6237 ) 
1.91E-90 25.8 
              
PC ae C36:3/ 
PC ae C34:3  
2204 
0.2875  
 (0.2275 -0.3474 ) 
1.28E-20 4.81 
              
PC ae C34:3/ 
PC ae C36:5 
2204 
0.3832   
(0.3275 -0.4389 ) 
6.63E-40 17.8 
              
PC ae C40:6/ 
PC ae C38:4  
2202 
0.1954  
 (0.1359 -0.2549 ) 
1.47E-10 6.31 
              
PC ae C42:4/ 
PC ae C40:4  
2202 
0.2263  
(0.1660 -0.2865 ) 
2.53E-13 3.91 
              
PC ae C42:4/ 





              
PC ae C44:4/ 
PC ae C44:5  
2201 
0.4018   
(0.3429 -0.4606 ) 
2.39E-39 8.38 
              
PC ae C44:6/ 





              
PC aa C42:0/ 
PC ae C42:5  
2204 
0.1273   
(0.0674 -0.1872 ) 
3.17E-05 5.08 
              
PC ae C40:5/ 





              
PC ae C42:3/ 
PC ae C42:2  
2202 
0.1701  
 (0.1113 -0.2289 ) 
1.59E-08 8.52 
              
PC ae C42:3/ 
PC ae C40:1  
2202 
0.2522  
 (0.1941 -0.3103 ) 
2.93E-17 10.8 
              
SM (OH) C22:2/ 





              
PC aa C40:5/ 
PC aa C36:5  
2203 
0.1419  
 (0.0809 -0.2029 ) 
5.31E-06 1.51 
              
PC aa C40:5/ 





              
PC aa C40:5/ 
PC aa C38:5  
2203 
0.1624  
 (0.1022 -0.2226 ) 
1.33E-07 4.16 
              
PC aa C36:3/ 
PC aa C36:4  
2201 
0.7445  
 (0.6919 -0.7971 ) 
1.71E-
145 26.7 
              
PC aa C36:3/ 
PC aa C38:4  
2204 
0.7213  
(0.6684 -0.7742 ) 
1.31E-
136 25.9 
              
PC aa C36:3/ 
PC aa C38:3  
2202 
0.1901  
 (0.1313 -0.2490 ) 
2.83E-10 8.42 
              
PC aa C36:3/ 
PC aa C38:5  
2201 
0.5330  
 (0.4772 -0.5888 ) 
8.70E-73 17.7 
              
PC aa C38:3/ 
PC aa C36:5  
2201 
0.2954  
 (0.2356 -0.3553 ) 
9.90E-22 5.23 
              
PC aa C38:3/ 
PC aa C38:4  
2204 
0.7252  
 (0.6728 -0.7776 ) 
4.85E-
140 27.2 
              
PC aa C38:3/ 
PC aa C36:4  
2204 
0.4537  
 (0.3972 -0.5103 ) 
6.76E-53 15.2 
              
PC aa C38:3/ 
PC aa C38:5  
2201 
0.4306   
(0.3721 -0.4892 ) 
4.08E-45 9.30 
              
PC ae C36:2/ 
PC ae C36:1  
2203 
0.1981  
 (0.1387 -0.2575 ) 
7.52E-11 6.66 
              
PC ae C36:2/ 
LysoPC a C17:0  
2202 
0.1847   
(0.1262 -0.2432 ) 
7.01E-10 9.52 
              
LysoPC a C18:2/ 
LysoPC a C20:4  
2204 
0.4978  
 (0.4401 -0.5556 ) 
2.28E-60 11.7 





 (0.0922 -0.2131 ) 
7.92E-07 1.89 
rs7156144 c PLEKHH1 14 intron variant 0.38 A 42.5 
PC ae C34:1/ 
PC ae C32:1  
2174 
0.2608  
 (0.2004 -0.3212 ) 
4.52E-17 4.80 
              
PC ae C34:3/ 
PC ae C36:5  
2178 
0.1955  
 (0.1377 -0.2532 ) 
3.96E-11 12.7 
rs11158519 c SYNE2 14 intron variant 5.24 A 13.5 
SM (OH) C22:2/ 
SM(OH)C22:1 
2209 
0.2092   
(0.1300 -0.2885 ) 
2.47E-07 13.4 
              






              
SM C16:1/ 





rs364585 c SPTLC3 20 intergenic variant 0.77 A 38.1 
SM (OH) C22:2/ 
SM C16:1  
2201 
0.1552  
 (0.0979 -0.2125 ) 
1.22E-07 6.56 
              
SM C16:1/ 





              
SM C16:1/ 





CADD, Combined Annotation Dependent Depletion; MAF, minor allele frequency 
a metabolite traits (µmol/L) were ln-transformed, outliers (>4 SD) were removed and metabolite traits were standardized, models are adjusted for age and sex; 
b significance threshold: 0.05/(19 × 61 Outcomes) = 4.31E-05; c reported in study from Illig et al. 20102; d reported in study from Shin et al. 2014 3;  
*Ensembl annotation version 84 (GRCh37)  
Supplementary Table S3. Replicated genetic variants and diabetes-associated metabolite traits with significant sex-interaction 
      Women Men  






N β (95% CI)a P-value Adj. R² 
in % 















1.06E-14 6.94 4.02E-14 








5.86E-07 2.73 6.36E-12 
MAF, minor allele frequency 
a metabolite traits (µmol/L) were ln-transformed, outliers (>4 SD) were removed and metabolite traits were standardized, models are adjusted for age; 
b  significance threshold for interaction of SNP with sex: 0.05/(19 SNPs × 61 Outcomes) = 4.31E-05; c reported in study from Shin et al. 2014 3; 
 
  
Supplementary Table S4. Exploratory identified exome chip variants and diabetes-associated metabolite traits with suggestive significance within 
EPIC-Potsdam 
Metabolite trait Exome chip 
name 













PC aa C36:3/ 
PC aa C36:4 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2201 1.16E-146 -0.7470 0.0268 5 prime UTR variant 3.57 
PC aa C38:3/ 
PC aa C38:4 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2204 2.09E-140 -0.7259 0.0267 5 prime UTR variant 3.57 
PC aa C36:3/ 
PC aa C38:4 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2204 4.07E-137 -0.7224 0.0270 5 prime UTR variant 3.57 
PC ae C36:3/ 
PC ae C38:5 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2204 1.13E-88 -0.5712 0.0270 5 prime UTR variant 3.57 
PC aa C36:3/ 
PC aa C38:5 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2201 3.06E-73 -0.5346 0.0284 5 prime UTR variant 3.57 
LysoPC a C18:2/ 
LysoPC a C20:4 
exm-
rs174546 rs174546 FADS1 11 C 66.6 2204 9.16E-60 -0.4984 0.0294 3 prime UTR variant 12.1 
PC aa C38:3/ 
PC aa C36:4 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2204 1.02E-52 -0.4546 0.0288 5 prime UTR variant 3.57 
PC ae C34:2/ 
PC ae C36:4 
exm-
rs174546 rs174546 FADS1 11 C 66.6 2203 1.15E-49 -0.4303 0.0282 3 prime UTR variant 12.1 
PC ae C34:2/ 
PC ae C38:5 
exm-
rs174546 rs174546 FADS1 11 C 66.6 2204 5.17E-49 -0.4323 0.0281 3 prime UTR variant 12.1 
PC aa C38:3/ 
PC aa C38:5 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2201 3.25E-45 -0.4310 0.0299 5 prime UTR variant 3.57 
PC ae C44:4/ 
PC ae C44:5 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2201 2.37E-39 -0.4024 0.0300 5 prime UTR variant 3.57 
PC ae C34:3/ 
PC ae C36:5 
exm-
rs174546 rs174546 FADS1 11 C 66.6 2204 5.05E-39 -0.3841 0.0284 3 prime UTR variant 12.1 
PC aa C40:5/ 
PC aa C36:3 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2204 1.41E-38 0.3831 0.0288 5 prime UTR variant 3.57 
SM C16:1/ 
PC aa C28:1 
exm-
rs7157785 rs7157785 SGPP1 14 G 83.6 2203 1.45E-35 0.4924 0.0389 
Regulatory region 
variant 1.91 
PC aa C36:3/ 
PC aa C36:5 
exm-





rs7157785 rs7157785 SGPP1 14 G 83.6 2202 2.79E-27 0.4234 0.0385 
Regulatory region 
variant 1.91 
PC aa C38:3/ 
PC aa C36:5 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2201 3.44E-21 -0.2956 0.0305 5 prime UTR variant 3.57 
PC ae C36:3/ 
PC ae C34:3 
exm-
rs174583 rs174583 FADS2 11 C 66.1 2204 2.39E-20 -0.2896 0.0306 intron variant 13.8 
Glycine exm2269212 rs4672596 CPS1 2 T 39.2 2203 1.73E-17 -0.2616 0.0303 intergenic 3.86 
PC ae C42:3/ 
PC ae C40:1 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2202 4.26E-17 -0.2536 0.0296 5 prime UTR variant 3.57 
PC ae C42:4/ 
PC ae C44:4 
exm-
rs174546 rs174546 FADS1 11 C 66.6 2200 8.67E-17 0.2586 0.0308 3 prime UTR variant 12.1 
PC ae C44:5/ 
PC ae C42:5 exm2269890 rs12641551 ACSL1 4 C 32.0 2202 1.21E-15 0.2537 0.0315 intron variant 3.93 
PC ae C42:5 exm-








SM(OH)C14:1 exm1106800 rs17751301 SYNE2 14 C 92.9 2202 1.22E-14 0.4382 0.0563 Arg1393Trp 10.1 
SM C16:1/ 
PC aa C28:1 exm1106800 rs17751301 SYNE2 14 C 92.9 2203 2.35E-14 0.4401 0.0573 Arg1393Trp 10.1 
PC ae C42:4/ 
PC ae C40:4 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2202 3.60E-13 -0.2270 0.0307 5 prime UTR variant 3.57 
Gly/Ser exm2269212 rs4672596 CPS1 2 T 39.2 2204 4.58E-13 -0.2238 0.0305 intergenic 3.86 
PC aa 40:5 exm-
rs174547 rs174547 FADS1 11 T 66.5 2203 5.16E-13 0.2197 0.0302 intron variant 3.57 
Tyr/Met exm572044 rs3204953 REV3L 6 C 85.2 2201 9.80E-12 -0.2841 0.0412 Val3064Ile 32.0 
PC aa C36:3/ 
PC aa C38:3 
exm-
rs174570 rs174570 FADS2 11 C 85.7 2202 3.63E-11 -0.2739 0.0412 intron variant 3.93 
PC ae C44:5 exm-
rs174547 rs174547 FADS1 11 T 66.5 2204 1.11E-10 0.2031 0.0305 intron variant 3.57 
PC ae C40:6/ 
PC ae C38:4 
exm-
rs174546 rs174546 FADS1 11 C 66.5 2202 1.28E-10 -0.1980 0.0303 3 prime UTR variant 12.1 
PC ae C36:2/ 
PC ae C36:1 
exm-
rs174547 rs174547 FADS1 11 T 66.5 2203 1.36E-10 -0.1973 0.0303 intron variant 3.57 
PC ae C36:2/ 
LysoPC a C17:0 
exm-
















rs364585 rs364585 SPTLC3 20 A 38.1 2202 6.78E-10 -0.1854 0.0298 intergenic 0.77 
PC aa C38:3/ 
PC ae C36:2 
exm-




rs680379 rs680379 SPTLC3 20 A 38.1 2202 1.12E-09 -0.1829 0.0298 intergenic 0.66 
PC ae C42:3/ 
PC ae C42:2 
exm-





PC aa C36:3/ 
PC aa C34:3 exm1219342 rs1136001 NTAN1 16 G 67.0 2201 5.58E-09 0.1835 0.0314 His283Asn 0.81 
PC aa C36:3/ 
PC aa C34:3 exm1219341 rs1135999 NTAN1 16 A 67.0 2201 5.58E-09 0.1835 0.0314 Ser287Pro 13.3 
PC aa C36:3/ 
PC aa C34:3 
exm-
rs7200543 rs7200543 PDXDC1 16 A 67.0 2201 5.58E-09 0.1835 0.0314 Synonymous variant 5.10 
PC ae C44:6/ 
PC aa C42:0 
exm-
rs174546 rs174546 FADS1 11 C 66.6 2204 7.79E-09 0.1799 0.0305 3 prime UTR variant 12.1 
PC aa C40:5/ 
PC aa C38:5 
exm-
rs499974 rs499974 MOGAT2 11 C 81.2 2203 2.25E-08 -0.2143 0.0379 
Downstream gene 
variant 8.66 
PC aa C36:1/ 
PC aa C34:1 exm858668 rs4751995 PNLIPRP2 10 A 47.6 2201 2.90E-08 -0.1692 0.0297 
intron variant/ splice 
region variant 10.4 
SM(OH)C22:2/ 
PC ae C38:2 
exm-
rs174546 rs174546 FADS1 11 C 66.5 2198 4.29E-08 0.1683 0.0306 3 prime UTR variant 12.1 
PC aa C36:1/ 
PC aa C34:1 exm858674 rs10885997 PNLIPRP2 10 A 58.8 2201 5.54E-08 -0.1697 0.0304 Synonymous variant 7.74 
SM(OH)C22:2/ 
SM(OH)C14:1 exm1107280 rs12881815 SYNE2 14 G 95.2 2202 6.95E-08 0.3677 0.0678 Glu4913Lys 25.2 
PC aa C42:1/ 








rs680379 rs680379 SPTLC3 20 A 38.1 2201 1.28E-07 0.1548 0.0292 intergenic 0.66 
SM(OH)C22:2/ 
SM(OH)C22:1 exm1479366 rs7412 APOE 19 C 91.4 2202 1.30E-07 -0.2677 0.0498 Arg202Cys 30.0 
PC aa C42:1/ 
PC aa C42:0 exm83510 rs41282494 CHIA 1 G 87.8 2200 1.33E-07 0.2465 0.0460 Asp47Asn 26.0 
PC aa C40:5/ 
PC aa C38:5 
exm-
rs174550 rs174550 FADS1 11 T 66.5 2203 1.38E-07 -0.1634 0.0307 5 prime UTR variant 3.57 
PC ae C44:6/ 
PC aa C42:1 
exm-
rs10790162 rs10790162 BUD13 11 A 6.70 2203 1.57E-07 -0.3201 0.0605 intron variant 6.55 
CAF, coded allele frequency; CADD, Combined Annotation Dependent Depletion; SE, standard error 
a gene variants are reported on the forward strand of NCBI build 37; b suggestive significance was defined as P < 1.64E-7 = (1E-5/ 61); 
c metabolite traits (µmol/L) were ln-transformed, outliers (>4 SD) were removed and metabolite traits were standardized, models are adjusted for age and sex; 
* Ensembl annotation version 84 (GRCh37) 
The FADS region is characterized by high linkage disequilibrium (LD); therefore, only the results for the top associated FADS variant for each metabolite trait are 
depicted. 
  
Supplementary Table S5. Identification of independent signals for CPS1, FADS1 and SGPP1/SYNE2 loci for selected metabolite traits within EPIC-Potsdam 
Metabolite trait Locus N SNPs in the 
model 
Coded allele Betaa SE P-valueb LD between 
SNPsc 
Glycine CPS1 2123 rs715 C 0.56937 0.03424 <.0001  
   rs4672596 A -0.02421 0.03224 0.4529 r²=0.2; D‘=0.8 
PC aa C36:3/ 
PC aa C36:4 
FADS1 2201 rs174550 G 2.14218 0.85492 0.0123 
 
   rs174547 G -1.39611 0.85505 0.1027 r²=1.0; D‘=1.0 
SM C16:1/ 
PC aa C28:1 
SGPP1/SYNE2 2137 rs7157785 A -0.52937 0.06265 <.0001 
 
   rs12881815 A -0.14242 0.07787 0.0675 r²=0.2; D‘=0.8 
   rs11158519 A 0.09414 0.06985 0.1778 r²=0.6; D‘=0.9 
LD, linkage disequilibrium; SE, standard error 
SNPs selected for the analysis on type 2 diabetes are depicted in bold 
a metabolites (µmol/L) were ln-transformed , outliers (>4 SD) were removed and z-transformation was applied, analyses were conducted to check for independent 
signals at each locus [Y= β1 SNP1 + β2 SNP2 (+ β3 SNP3) + β4 age + β5 sex + n]; b significant SNPs (in bold) were selected for type 2 diabetes analyses;  
c depicted values for LD between respective SNP in that row and selected SNP for type 2 diabetes analysis (in bold)  
  
Supplementary Table S6. Exploratory identified exome chip variants and diabetes-associated metabolite traits with significant sex-interaction within 
EPIC-Potsdam 
EPIC-Potsdam  KORA F4 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CAF, coded allele frequency; CADD, Combined Annotation Dependent Depletion; SE, standard error 
a metabolite traits (µmol/L) were ln-transformed, outliers (>4 SD) were removed and metabolite traits were standardized, models are adjusted for age; b significance 
threshold for interaction of SNP with sex: 1E-05/61 Outcomes = 1.64E-07; * Ensembl annotation version 84 (GRCh37)  
Supplementary Table S7. Summary of biologic pathway annotations from KEGG database 
Chr Locus SNP Entrez gene 
ID 
Annotated gene set flanking width 
around the SNP (+/- kb)
KEGG pathway 
1 CHIA rs41282494 27159 CHIA 500 hsa00520  Amino sugar and nucleotide sugar metabolism 
1 PHGDH * rs541503 26227 PHGDH 500 
hsa00260  Glycine, serine and threonine metabolism 
hsa01100  Metabolic pathways 
hsa01130  Biosynthesis of antibiotics 
hsa01200  Carbon metabolism 
hsa01230  Biosynthesis of amino acids 
2 CPS1 * rs715 1373 CPS1 500 
hsa00220  Arginine biosynthesis 
hsa00250  Alanine, aspartate and glutamate metabolism 
hsa00910  Nitrogen metabolism 
hsa01100  Metabolic pathways 
hsa01200  Carbon metabolism 
hsa01230  Biosynthesis of amino acids 
2 CPS1 rs4672596 
29034 CPS1 intronic transcript 1 200000 x 
1373 CPS1 200000 
hsa00220  Arginine biosynthesis 
hsa00250  Alanine, aspartate and glutamate metabolism 
hsa00910  Nitrogen metabolism 
hsa01100  Metabolic pathways 
hsa01200  Carbon metabolism 
hsa01230  Biosynthesis of amino acids 
4 ACSL1 * rs12641551 
100500818 MIR3945 10000 x 
100616111 MIR4455 100000 x 
2180 ACSL1 100000 
hsa00061  Fatty acid biosynthesis 
hsa00071  Fatty acid degradation 
hsa01100  Metabolic pathways 
hsa01212  Fatty acid metabolism 
hsa03320  PPAR signaling pathway 
hsa04146  Peroxisome 
hsa04920  Adipocytokine signaling pathway 
643036 SLED1 100000 x 
5 SLC22A4, OCTN1 * rs272893 
553103 LOC553103 500 x 
6583 SLC22A4 500 hsa05231  Choline metabolism in cancer 
6 ELOVL2 * rs9393903 54898 ELOVL2 500 
hsa00062  Fatty acid elongation 
hsa01040  Biosynthesis of unsaturated fatty acids 
hsa01212  Fatty acid metabolism 
6 REV3L rs3204953 5980 REV3L 500 
hsa01100  Metabolic pathways 
hsa03460  Fanconi anemia pathway 
10 SCD * rs603424 9033 PKD2L1 500 x 
10 PNLIPRP2 rs4751995 5408 PNLIPRP2 500 
hsa00561  Glycerolipid metabolism 
hsa01100  Metabolic pathways 
hsa04972  Pancreatic secretion 
hsa04975  Fat digestion and absorption 






3992 FADS1 500 
hsa01040  Biosynthesis of unsaturated fatty acids 







9415 FADS2 500 
hsa00592  alpha-Linolenic acid metabolism 
hsa01040  Biosynthesis of unsaturated fatty acids 
hsa01212  Fatty acid metabolism 
hsa03320  PPAR signaling pathway 
11 MOGAT2 rs499974 
4135 MAP6 100000 x 
80168 MOGAT2 100000 
hsa00561  Glycerolipid metabolism 
hsa04975  Fat digestion and absorption 
283214 LOC283214 100000 x 
84649 DGAT2 100000 
hsa00561  Glycerolipid metabolism 
hsa01100  Metabolic pathways 
hsa04975  Fat digestion and absorption 
7405 UVRAG 100000 x 
11 BUD13 rs10790162 84811 BUD13 500 x 
12 PAH * rs1718306 5053 PAH 500 
hsa00360  Phenylalanine metabolism 
hsa00400  Phenylalanine, tyrosine and tryptophan biosynthesis 
hsa01100  Metabolic pathways 
hsa01230  Biosynthesis of amino acids 
14 PLEKHH1 * rs7156144 161145 TMEM229B/ C14orf83 500 x 
14 SGPP1 rs7157785 
81537 SGPP1 100000 
hsa00600  Sphingolipid metabolism 
hsa04071  Sphingolipid signaling pathway 
23224 SYNE2 100000 x 
16 NTAN1 rs1135999 
23042 PDXDC1 500 x 
102724985 LOC102724985 500 x 
123803 NTAN1 500 x 
19 APOE rs7412 348 APOE 500 hsa05010  Alzheimer's disease 
20 SPTLC3 * rs364585 
100505515 LOC100505515 100000 x 
101929486 LOC101929486 100000 x 
55304 SPTLC3 100000 
hsa00600  Sphingolipid metabolism 
hsa01100  Metabolic pathways 
hsa04071  Sphingolipid signaling pathway 
* as annotated by Illig et al 2010 2 and Shin et al. 2014 3 
  
Supplementary Table S8. Suggestive gene-based associations with metabolite traits using SKAT and burden test in EPIC-Potsdama 




PC aa C42:1/PC aa C42:0 GFRAL 6 0 1.54E-05 2.15E-06 
PC ae C32:1/PC ae C32:2 PARP2 3 0 4.95E-06 4.00E-06 
PC ae C34:2/PC ae C36:3 OCA2 4 0 8.06E-06 1.28E-06 
PC ae C40:6 TMC5 4 0 1.80E-05 6.01E-06 
PC ae C42:4/PC ae C44:4 OR10J1 3 1 4.91E-06 2.64E-06 
SM (OH) C22:2/SM C24:0 GPR156 1 1 6.15E-06 6.15E-06 
PC aa C36:3/PC aa C36:5 TDRD5 3 2 2.56E-04 1.36E-06 
PC aa C36:3/PC aa C38:5 TDRD5 3 2 1.49E-03 6.20E-06 
SM (OH) C22:2/SM C18:0 BIN1 2 0 7.98E-05 1.50E-06 
PC aa C32:1/PC aa C34:1 ZBTB7C 2 0 2.78E-07 5.24E-05 
PC aa C32:1 ZBTB7C 2 0 5.14E-06 1.36E-04 
PC aa C32:1/ LysoPC a C18:1 ZBTB7C 2 0 2.31E-06 2.96E-04 
SM (OH) C22:2/SM C16:1 TFRC 3 0 1.66E-06 7.53E-04 
a only sub-cohort; analysis was adjusted for age and sex; b rare variants defined as MAF ≤	 ଵ
√ଶ௡
 (≤ 0.015 EPIC-Potsdam); 
c significance threshold was defined as P < 0.05/[number of genes with >1 variants (ranging from 7243 to 7332)] 
  
Supplementary Table S9. Single SNP associations included within gene-based analyses in EPIC-Potsdam and KORA F4 
     EPIC-Potsdam KORA F4 pooled 
Metabolite 
trait 


















BIN1 2 exm2254544 rs1060743 2202 0.0001 (0.0325) 0.9982 72.0% A 2692 
0.0021 
(0.0276) 0.9385 70.0% A 
0.0013 
(0.0210) 0.9522 
    2 exm2263907 rs755639 2202 -0.0263 (0.0305) 0.3897 40.9% C 2692 
-0.0227 






TFRC 3 exm376168 rs3817672 2201 0.0330 (0.0299) 0.2704 45.4% C 2688 
-0.0022 
(0.0262) 0.9343 43.4% C 
0.0131 
(0.0197) 0.5066 
    3 exm-rs11915082 rs11915082 2201 
0.0264 
(0.0302) 0.3822 61.1% G 2688 
-0.0047 
(0.0262) 0.8588 59.0% G 
0.0087 
(0.0198) 0.6619 
    3 exm-rs9859260 rs9859260 2201 
0.0078 
(0.0304) 0.7969 40.0% C 2688 
-0.0208 







GFRAL 6 exm2270477 rs1007968 2200 0.0263 (0.0300) 0.3858 54.2% C 2691 
-0.0395 
(0.0266) 0.1381 54.2% C 
-0.0081 
(0.0329) 0.8062 
    6 exm556728 rs12199003 2200 -0.0629 (0.0311) 0.0459 61.4% C 2692 
0.0147 
(0.0275) 0.5939 60.5% C 
-0.0227 
(0.0388) 0.5576 
    6 exm556737 rs147652095 2200 -0.0497 (0.1125) 0.6626 98.2% G 2692 
-0.0935 
(0.0973) 0.3366 98.1% G 
-0.0748 
(0.0736) 0.3097 
    6 exm556738 rs115053739 2200 -0.0497 (0.1125) 0.6626 98.2% G 2692 
-0.1046 
(0.0982) 0.2866 98.1% G 
-0.0809 
(0.0740) 0.2744 
    6 exm556756 rs146300118 2200 -0.0497 (0.1125) 0.6626 98.2% A 2692 
-0.1075 
(0.0977) 0.2712 98.1% A 
-0.0826 
(0.0738) 0.2625 
    6 exm556777 rs9370418 2200 0.0320 (0.0333) 0.3415 29.0% T 2692 
-0.0829 
(0.0303) 0.0062 26.8% T 
-0.0263 
(0.0574) 0.6473 
CAF, coded allele frequency; GC, genomic control; SE, standard error 
a metabolite traits (µmol/L) were ln-transformed, outliers (>4 SD) were removed and metabolite traits were standardized, effect estimates are adjusted for age and sex 
  
Supplementary Table S10. Suggestive gene-based associations including functional exome chip variants with metabolite traits using SKAT and burden 
test in EPIC-Potsdama 




[Ile+ Leu]/Met PCNXL3 1 1 3.14E-05 3.14E-05 
Val/[Ile+ Leu] DNAH6 3 2 3.27E-04 1.35E-05 
PC ae C36:2/PC aa C36:2 OCA2 2 0 1.64E-05 7.83E-05 
PC aa C38:3/LysoPC a C20:3 COL11A2 2 0 4.75E-06 2.63E-07 
PC aa C38:3/LysoPC a C18:1 COL11A2 2 0 4.45E-06 4.67E-07 
PC aa C36:3/PC aa C38:5 DNAJC13 2 1 2.31E-05 9.60E-05 
H1 OR51Q1 2 1 8.85E-06 9.62E-06 
a only sub-cohort; analysis was adjusted for age and sex; b rare variants defined as MAF ≤	 ଵ
√ଶ௡
 (≤ 0.015 EPIC-Potsdam);  
c significance threshold was defined as P < 0.05/[number of genes with >1 variants (ranging from 1449 to 1492)] 
Functional variants were defined based on the Charge annotation list: column “sc_damaging”. 
  
Supplementary Table S11. Single SNP associations included within functional gene-based analyses in EPIC-Potsdam and KORA F4 
 
EPIC-Potsdam KORA F4 pooled 
Metabolite 
trait 
















H1 OR51Q1 11 exm882803 rs151161477 2192 0.0819 (0.1329) 0.5389 98.79% G 2676 
0.0670 
(0.1211) 0.5803 98.92% G 
0.0738 
(0.0895) 0.4100 
    
11 exm882826 rs58283839 2192 -0.1609 (0.1214) 0.1864 98.43% A 2676 
-0.0781 
(0.09381) 0.4054 98.21% A 
-0.1090 
(0.0742) 0.1419 
    
11 exm882840 rs2647574 2192 -0.0097 (0.0308) 0.7526 61.13% C 2676 
0.0019 
(0.0259) 0.9420 60.70% G 
-0.0029 
(0.0198) 0.8823 
CAF, coded allele frequency; GC, Genomic control; SE, standard error 
a metabolite traits (µmol/L) were ln-transformed, outliers (>4 SD) were removed and metabolite traits were standardized, effect estimates are adjusted for age and sex 
  
Supplementary Table S12. Exclusion of top variants from the gene-based analyses for genes (>2 variants) with metabolite traits using SKAT and 
burden test in EPIC-Potsdama 




SM (OH) C22:2/ 
SM C16:1 TFRC 3 
 1.66E-06 7.53E-04 
   - rs3817672 2.29E-06 0.7711 
PC aa C42:1/ 
PC aa C42:0 
GFRAL  6   1.54E-05 2.15E-06 
     - rs12199003 1.15E-05 8.89E-07 
   - rs146300118 3.17E-05 2.54E-06 
   - rs146300118 - rs115053739 0.0008 2.33E-05 
   - rs146300118 - rs115053739 - rs147652095 0.1116 0.052 
H1 OR51Q1 11  8.85E-06 9.62E-06 
   - rs58283839 0.01 0.01 
a only sub-cohort; b excluded from setID file, selection was based on the pooled p-value from single SNP analyses (Supplementary Table S9, 11 ); 
c Original p-values in bold, analysis was adjusted for age and sex; 
  
Supplementary Table S13. Gene-based associations of identified genes with diabetes risk using SKAT and burden test in EPIC-Potsdam 
 
Metabolite trait Gene Nr. of common 
variantsa 






PC aa C42:1/PC aa C42:0 GFRAL 6 0 5.79E-01 8.38E-01 
SM (OH) C22:2/SM C18:0 BIN1 2 0 7.86E-01 7.43E-01 
SM (OH) C22:2/SM C16:1 TFRC 3 0 4.52E-01 1.32E-01 
H1 OR51Q1 2 1 6.53E-01 9.83E-01 
a rare variants defined as MAF ≤	 ଵ
√ଶ௡
 (≤ 0.013 EPIC-Potsdam);  
b significance threshold was defined as P < 0.05 
  
Supplementary Table S14. Identified loci and their function in human metabolism 
Locus Entrez Gene ID* Name* Function* 
PHGDH 26227 phosphoglycerate dehydrogenase 
Enzyme which is involved in the early steps of L-serine 
synthesis in animal cells. L-serine is required for D-serine 
and other amino acid synthesis. 
CPS1 1373 carbamoyl-phosphate synthase 1 
The mitochondrial enzyme encoded by this gene catalyses 
synthesis of carbamoyl phosphate from ammonia and 
bicarbonate. This reaction is the first committed step of the 
urea cycle, which is important in the removal of excess urea 
from cells. The encoded protein may also represent a core 
mitochondrial nucleoid protein. 
ACSL1 2180 acyl-CoA synthetase long-chain family member 1 
The protein encoded by this gene is an isozyme of the long-
chain fatty-acid-coenzyme A ligase family. Although differing 
in substrate specificity, subcellular localization, and tissue 
distribution, all isozymes of this family convert free long-
chain fatty acids into fatty acyl-CoA esters, and thereby play 
a key role in lipid biosynthesis and fatty acid degradation. 
SLC22A4, OCTN1 6583 solute carrier family 22 member 4 
Protein is an organic cation transporter and plasma integral 
membrane protein containing eleven putative 
transmembrane domains as well as a nucleotide-binding site 
motif. Polyspecific organic cation transporters in the liver, 
kidney, intestine, and other organs are critical for elimination 
of many endogenous small organic cations as well as a wide 
array of drugs and environmental toxins. 
ELOVL2 54898 ELOVL fatty acid elongase 2 
ELOVL2 encodes for a transmembrane protein involved in 
the synthesis of long-chain polyunsaturated fatty acids 
(PUFA) [Leonard AE et al. Identification and expression of 
mammalian long-chain PUFA elongation enzymes. Lipids. 
2002; 37(8): 733-40.] 
REV3L 5980 
REV3 like, DNA directed 
polymerase zeta catalytic 
subunit 
Encodes the REV3L which is a specialized DNA polymerase 
essential for DNA damage-induced mutagenesis [Gibbs PE 
et al. A human homolog of the Saccharomyces cerevisiae 
REV3 gene, which encodes the catalytic subunit of DNA 
polymerase zeta. Proc Natl Acad Sci U S A. 1998; 95(12): 
6876-80.] 
SCD 6319 stearoyl-CoA desaturase (delta-9-desaturase) 
This gene encodes an enzyme involved in fatty acid 
biosynthesis, primarily the synthesis of oleic acid. The 
protein belongs to the fatty acid desaturase family and is an 
integral membrane protein located in the endoplasmic 
reticulum. 
PNLIPRP2 5408 pancreatic lipase related protein 2  
This gene encodes a lipase that hydrolyzes galactolipids, the 
main components of plant membrane lipids.  
FADS1 3992 fatty acid desaturase 1  The protein encoded by this gene is a member of the fatty 
acid desaturase (FADS) gene family. Desaturase enzymes 
regulate unsaturation of fatty acids through the introduction 
of double bonds between defined carbons of the fatty acyl 
chain.  
FADS2 9415 fatty acid desaturase 2 
MOGAT2 80168 monoacylglycerol O-acyltransferase 2 
The protein encoded by this gene is an enzyme that 
catalyses the synthesis of diacylglycerol from 2-
monoacylglycerol and fatty acyl-CoA. The encoded protein is 
important in the uptake of dietary fat by the small intestine. 
This protein forms a complex with diacylglycerol O-
acyltransferase 2 in the endoplasmic reticulum, and this 
complex catalyses the synthesis of triacylglycerol. 
PAH 5053 phenylalanine hydroxylase 
PAH encodes the enzyme phenylalanine hydroxylase that is 
the rate-limiting step in phenylalanine catabolism. Deficiency 
of this enzyme activity results in the autosomal recessive 
disorder phenylketonuria. 
PLEKHH1 57475 pleckstrin homology, MyTH4 and FERM domain containing H1 NA 
SGPP1 81537 sphingosine-1-phosphate phosphatase 1 
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid 
metabolite that regulates diverse biologic processes. SGPP1 
catalyses the degradation of S1P via salvage and recycling 
of sphingosine into long-chain ceramides 
NTAN1 123803 N-terminal asparagine amidase 
The protein encoded by this gene functions in a step-wise 
process of protein degradation through the N-end rule 
pathway. This protein acts as a tertiary destabilizing enzyme 
that deamidates N-terminal L-Asn residues on proteins to 
produce N-terminal L-Asp. L-Asp substrates are 
subsequently conjugated to L-Arg, which is recognized by 
specific E3 ubiquitin ligases and targeted to the proteasome. 
APOE 348 apolipoprotein E 
The protein encoded by this gene is a major apoprotein of 
the chylomicron. It binds to a specific liver and peripheral cell 
receptor, and is essential for the normal catabolism of 
triglyceride-rich lipoprotein constituents. Mutations in this 
gene result in familial dysbetalipoproteinemia, or type III 
hyperlipoproteinemia (HLP III), in which increased plasma 
cholesterol and triglycerides are the consequence of 
impaired clearance of chylomicron and VLDL remnants. 
SPTLC3 55304 serine palmitoyltransferase long chain base subunit 3 
The SPTLC3 gene encodes an isoform of the third subunit of 
serine palmitoyltransferase (SPT; EC 2.3.1.50), which 
catalyses the rate-limiting step of the de novo synthesis of 
sphingolipids.  
*According to the NCBI database if not otherwise stated 4 
  
Supplementary Table S15. List of selected candidate SNPs 
SNP Locus Chr Position Study Proxy r² D’ 
rs211718 ACADM 1 76106675 Illig et al. 2010 2       
rs541503 PHGDH 1 120208297 Illig et al. 2010 2       
rs2286963 ACADL 2 211060050 Illig et al. 2010 2       
rs715 CPS1 2 211543055 Shin et al. 2014 3       
rs8396 ETFDH 4 159630817 Illig et al. 2010 2       
rs12641551 ACSL1 4 185767941 Illig et al. 2010 2 *(rs2046813) 1 1
rs272893 SLC22A4, OCTN1 5 131663062 Illig et al. 2010 2 *(rs272889) 1 1
rs329319 JADE2 5 133906609 Shin et al. 2014 3       
rs9393903 ELOVL2 6 11042909 Illig et al. 2010 2       
rs603424 SCD 10 102075479 Illig et al. 2010 2       
rs174547 FADS1 11 61570783 Illig et al. 2010 2       
rs2014355 ACADS 12 121175524 Illig et al. 2010 2       
rs4761007 intergenic 12 127924890 Shin et al. 2014 3       
rs1718306 PAH 12 103257308 Shin et al. 2014 3       
rs7156144 PLEKHH1 14 67979713 Illig et al. 2010 2       
rs11158519 SYNE2 14 64364585 Illig et al. 2010 2       
rs10459872 C16orf46 16 81094951 Shin et al. 2014 3 *(rs804895) 1 1
rs364585 SPTLC3 20 12962718 Illig et al. 2010 2 *(rs168622) 1 1
rs11578 STX16 20 57253275 Shin et al. 2014 3       
* indicates that in the present analysis a proxy SNP in LD of the originally reported GWAS hit (shown in parenthesis) was analyzed 
  
Supplementary Table S16. List of selected metabolite traits (single metabolites, metabolite ratios and factors) 
Abbreviation Biochemical name  




SM C16:1 Sphingomyelin C 16:1 
PC ae C34:3 Phosphatidylcholine acyl-alkyl C 34:3 
PC ae C40:6 Phosphatidylcholine acyl-alkyl C 40:6 
PC ae C42:5  Phosphatidylcholine acyl-alkyl C 42:5 
PC ae C44:4 Phosphatidylcholine acyl-alkyl C 44:4 
PC ae C44:5 Phosphatidylcholine acyl-alkyl C 44:5 
PC aa C32:1 Phosphatidylcholine diacyl C 32:1 
PC aa C36:1 Phosphatidylcholine diacyl C 36:1 
PC aa C38:3 Phosphatidylcholine diacyl C 38:3 
PC aa C40:5 Phosphatidylcholine diacyl C 40:5 
LysoPC a C18:2 Lysophosphatidylcholine acyl C18:2 
Factors   
Factor 1 = (0.80×PC ae C32:1) + (0.78×PC ae C32:2) + (0.70×PC ae C34:2) + 
(0.72×PC ae C34:3) + (0.71×PC ae C36:2) + (0.71×PC ae C36:3) + (0.85×PC 
ae C40:5) + (0.76×PC ae C40:6) + (0.82×PC ae C42:3) + (0.85×PC ae C42:4) 
+ (0.87×PC ae C42:5) + (0.76×PC ae C44:4) + (0.78× PC ae C44:5) + 
(0.83×PC ae C44:6) + (0.82×PC aa C42:0) + (0.79×PC aa C42:1) + (0.54×SM 
C16:1) + (0.57× SM OH C22:2) + (0.41×lysoPC a C17:0) 
 Factors were derived based on standardized (mean=0; SD=1) single metabolites 
Factor 2= (0.55×propionylcarnitine) +(0.66×phe) + (0.61× trp) + (0.66×tyr) + 
(0.68×val) + (0.66×[ile + leu]) + (0.59×PC aa C32:1) + (0.70×PC aa C36:1)+ 
(0.65×PC aa C36:3) + (0.76× PC aa C38:3) + (0.72×PC aa C40:4) + (0.71× PC 
aa C40:5) + (0.44×h1) 
 Factors were derived based on standardized (mean=0; SD=1) single metabolites 
Ratios amino acids   
Val/[Ile+ Leu] Valine/[Isoleucine + Leucine] 







Ratios Acylcarnitines   
C3/C0 Propionyl-L-carnitine/DL-Carnitine 
Ratios MUFAs   
PC ae C32:1/PC ae C32:2 Phosphatidylcholine acyl-alkyl C 32:1/Phosphatidylcholine acyl-alkyl C 32:1 
PC ae C34:1/PC ae C32:1 Phosphatidylcholine acyl-alkyl C 34:1/Phosphatidylcholine acyl-alkyl C 32:1 
Ratios PUFAs (C34-C40)   
PC ae C34:2/PC ae C38:5 Phosphatidylcholine acyl-alkyl C 34:2/Phosphatidylcholine acyl-alkyl C 38:5 
PC ae C34:2/PC ae C36:4 Phosphatidylcholine acyl-alkyl C 34:2/Phosphatidylcholine acyl-alkyl C 36:4 
PC ae C34:2/PC ae C36:3 Phosphatidylcholine acyl-alkyl C 34:2/Phosphatidylcholine acyl-alkyl C 36:3 
PC ae C36:3/PC ae C38:5 Phosphatidylcholine acyl-alkyl C 36:3/Phosphatidylcholine acyl-alkyl C 38:5 
PC ae C36:3/PC ae C34:3 Phosphatidylcholine acyl-alkyl C 36:3/Phosphatidylcholine acyl-alkyl C 34:3 
PC ae C34:3/PC ae C36:5 Phosphatidylcholine acyl-alkyl C 34:3/Phosphatidylcholine acyl-alkyl C 36:5 
PC ae C40:6/PC ae C38:4 Phosphatidylcholine acyl-alkyl C 40:6/Phosphatidylcholine acyl-alkyl C 38:4 
PC ae C40:6/PC aa C38:0 Phosphatidylcholine acyl-alkyl C 40:6/Phosphatidylcholine diacyl  C 38:0 
PC ae C40:6/PC aa C38:6 Phosphatidylcholine acyl-alkyl C 40:6/Phosphatidylcholine diacyl  C 38:6 
Ratios PUFAs (C40-C44)   
PC ae C42:4/PC ae C40:4 Phosphatidylcholine acyl-alkyl C 42:4/Phosphatidylcholine acyl-alkyl C 40:4 
PC ae C42:4/PC ae C44:4 Phosphatidylcholine acyl-alkyl C 42:4/Phosphatidylcholine acyl-alkyl C 44:4 
PC ae C44:4/PC ae C44:5 Phosphatidylcholine acyl-alkyl C 44:4/Phosphatidylcholine acyl-alkyl C 44:5 
PC ae C44:5/PC ae C44:6 Phosphatidylcholine acyl-alkyl C 44:5/Phosphatidylcholine acyl-alkyl C 44:6 
PC ae C44:5/PC ae C42:5 Phosphatidylcholine acyl-alkyl C 44:5/Phosphatidylcholine acyl-alkyl C 42:5 
PC ae C44:6/PC aa C42:1 Phosphatidylcholine acyl-alkyl C 44:6/Phosphatidylcholine diacyl  C 42:1 
PC ae C44:6/PC aa C42:0 Phosphatidylcholine acyl-alkyl C 44:6/Phosphatidylcholine diacyl  C 42:0 
PC aa C32:1/PC aa C34:1 Phosphatidylcholine diacyl  C 32:1/Phosphatidylcholine diacyl  C 34:1 
PC aa C42:1/PC aa C42:0 Phosphatidylcholine diacyl  C 42:1/Phosphatidylcholine diacyl  C 42:0 
PC aa C42:0/PC ae C42:5 Phosphatidylcholine diacyl  C 42:0/Phosphatidylcholine diacyl  C 42:5 
PC ae C42:5/PC ae C40:4 Phosphatidylcholine acyl-alkyl C 42:5/Phosphatidylcholine acyl-alkyl C 40:4 
PC ae C40:5/PC ae C42:5 Phosphatidylcholine acyl-alkyl C 40:5/Phosphatidylcholine acyl-alkyl C 42:5 
PC ae C40:5/PC aa C42:2 Phosphatidylcholine acyl-alkyl C 40:5/Phosphatidylcholine diacyl  C 42:2 
PC ae C40:5/PC ae C36:0 Phosphatidylcholine acyl-alkyl C 40:5/Phosphatidylcholine acyl-alkyl C 36:0 
PC ae C42:3/PC ae C42:2 Phosphatidylcholine acyl-alkyl C 42:3/Phosphatidylcholine acyl-alkyl C 42:2 
PC ae C42:3/PC ae C40:1 Phosphatidylcholine acyl-alkyl C 42:3/Phosphatidylcholine acyl-alkyl C 40:1 
Ratios Sphingomyelins   
SM(OH)C22:2/SM(OH)C22:1 Hydroxysphingomyelin C 22:2/Hydroxysphingomyelin C 22:1 
SM(OH)C22:2/SM C24:1 Hydroxysphingomyelin C 22:2/Sphingomyelin C 24:1 
SM(OH)C22:2/SM C24:0 Hydroxysphingomyelin C 22:2/Sphingomyelin C 24:0 
SM(OH)C22:2/PC ae C38:2 Hydroxysphingomyelin C 22:2/Phosphatidylcholine acyl-alkyl C 38:2 
SM(OH)C22:2/SM C16:1 Hydroxysphingomyelin C 22:2/Sphingomyelin C 16:1 
SM(OH)C22:2/SM C18:1 Hydroxysphingomyelin C 22:2/Sphingomyelin C 18:1 
SM(OH)C22:2/SM(OH)C14:1 Hydroxysphingomyelin C 22:2/Hydroxysphingomyelin C 14:1 
SM(OH)C22:2/SM C18:0 Hydroxysphingomyelin C 22:2/Sphingomyelin C 18:0 
SM C16:1/SM C16:0 Sphingomyelin C 16:1/Sphingomyelin C 16:0 
SM C16:1/SM C18:0 Sphingomyelin C 16:1/Sphingomyelin C 18:0 
SM C16:1/SM C18:1 Sphingomyelin C 16:1/Sphingomyelin C 18:1 
SM C16:1/PC aa C28:1 Sphingomyelin C 16:1/Phosphatidylcholine diacyl  C 28:1 
Ratios Diacyl-Phophatidylcholines/Lyso-Phosphatidylcholines   
PC aa C40:4/PC aa C42:6 Phosphatidylcholine diacyl  C 40:4/Phosphatidylcholine diacyl  C 42:6 
PC aa C40:4/PC aa C40:5 Phosphatidylcholine diacyl  C 40:4/Phosphatidylcholine diacyl  C 40:5 
PC aa C40:5/PC aa C42:5 Phosphatidylcholine diacyl  C 40:5/Phosphatidylcholine diacyl  C 42:5 
PC aa C40:5/PC aa C38:6 Phosphatidylcholine diacyl  C 40:5/Phosphatidylcholine diacyl  C 38:6 
PC aa C40:5/PC aa C40:6 Phosphatidylcholine diacyl  C 40:5/Phosphatidylcholine diacyl  C 40:6 
PC aa C40:5/PC aa C36:5 Phosphatidylcholine diacyl  C 40:5/Phosphatidylcholine diacyl  C 36:5 
PC aa C40:5/PC aa C36:3 Phosphatidylcholine diacyl  C 40:5/Phosphatidylcholine diacyl  C 36:3 
PC aa C40:5/PC aa C38:5 Phosphatidylcholine diacyl  C 40:5/Phosphatidylcholine diacyl  C 38:5 
PC aa C36:3/PC aa C36:5 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 36:5 
PC aa C36:3/PC aa C34:3 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 34:3 
PC aa C36:3/LysoPC a C18:1 Phosphatidylcholine diacyl  C 36:3/Lysophosphatidylcholine acyl C18:1 
PC aa C36:3/PC aa C36:4 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 36:4 
PC aa C36:3/PC aa C38:4 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 38:4 
PC aa C36:3/PC aa C38:3 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 38:3 
PC aa C36:3/PC ae C38:3 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 38:3 
PC aa C36:3/PC aa C38:5 Phosphatidylcholine diacyl  C 36:3/Phosphatidylcholine diacyl  C 38:5 
PC aa C38:3/PC aa C36:5 Phosphatidylcholine diacyl  C 38:3/Phosphatidylcholine diacyl  C 36:5 
PC aa C38:3/PC aa C38:4 Phosphatidylcholine diacyl  C 38:3/Phosphatidylcholine diacyl  C 38:4 
PC aa C38:3/LysoPC a C20:3 Phosphatidylcholine diacyl  C 38:3/Lysophosphatidylcholine acyl C20:3 
PC aa C38:3/PC aa C36:4 Phosphatidylcholine diacyl  C 38:3/Phosphatidylcholine diacyl  C 36:4 
PC aa C38:3/LysoPC a C18:1 Phosphatidylcholine diacyl  C 38:3/Lysophosphatidylcholine acyl C18:1 
PC aa C38:3/PC ae C36:2 Phosphatidylcholine diacyl  C 38:3/Phosphatidylcholine acyl-alkyl C 36:2 
PC aa C38:3/PC ae C38:3 Phosphatidylcholine diacyl  C 38:3/Phosphatidylcholine acyl-alkyl C 38:3 
PC aa C38:3/PC aa C38:5 Phosphatidylcholine diacyl  C 38:3/Phosphatidylcholine diacyl  C 38:5 
PC ae C36:2/PC aa C32:2 Phosphatidylcholine acyl-alkyl C 36:2/Phosphatidylcholine diacyl  C 32:2 
PC ae C36:2/PC aa C36:2 Phosphatidylcholine acyl-alkyl C 36:2/Phosphatidylcholine diacyl  C 36:2 
PC ae C36:2/PC ae C36:1 Phosphatidylcholine acyl-alkyl C 36:2/Phosphatidylcholine acyl-alkyl C 36:1 
PC ae C36:2/LysoPC a C17:0 Phosphatidylcholine acyl-alkyl C 36:2/Lysophosphatidylcholine acyl C17:0 
PC aa C36:1/LysoPC a C18:1 Phosphatidylcholine diacyl  C 36:1/Lysophosphatidylcholine acyl C18:1 
PC aa C36:1/PC aa C36:2 Phosphatidylcholine diacyl  C 36:1/Phosphatidylcholine diacyl  C 36:2 
PC aa C36:1/PC aa C34:2 Phosphatidylcholine diacyl  C 36:1/Phosphatidylcholine diacyl  C 34:2 
PC aa C36:1/PC aa C34:1 Phosphatidylcholine diacyl  C 36:1/Phosphatidylcholine diacyl  C 34:1 
PC aa C32:1/LysoPC a C16:1 Phosphatidylcholine diacyl  C 32:1/Lysophosphatidylcholine acyl C16:1 
PC aa C32:1/LysoPC a C18:1 Phosphatidylcholine diacyl  C 32:1/Lysophosphatidylcholine acyl C18:1 
PC aa C32:1/PC aa C32:2 Phosphatidylcholine diacyl  C 32:1/Phosphatidylcholine diacyl  C 32:2 
LysoPC a C17:0/LysoPC a C18:0 Lysophosphatidylcholine acyl C17:0/Lysophosphatidylcholine acyl C18:0 
LysoPC a C17:0/LysoPC a C16:0 Lysophosphatidylcholine acyl C17:0/Lysophosphatidylcholine acyl C16:0 
LysoPC a C18:2/LysoPC a C20:4 Lysophosphatidylcholine acyl C18:2/Lysophosphatidylcholine acyl C20:4 
LysoPC a C18:2/LysoPC a C18:0 Lysophosphatidylcholine acyl C18:2/Lysophosphatidylcholine acyl C18:0 
LysoPC a C18:2/PC aa C36:2 Lysophosphatidylcholine acyl C18:2/Phosphatidylcholine diacyl  C 36:2 
LysoPC a C18:2/LysoPC a C18:1 Lysophosphatidylcholine acyl C18:2/Lysophosphatidylcholine acyl C18:1 
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